We are live on ! Find out more
WIM

Woodford Investment Management Portfolio holdings

AUM $310M
1-Year Est. Return 17.41%
This Fund
S&P 500
This Quarter Est. Return
-4.65%
1 Year Est. Return
-17.41%
3 Year Est. Return
-27.14%
5 Year Est. Return
+68.29%
10 Year Est. Return
–
AUM
$1.12B
AUM Growth
-$359M
Cap. Flow
-$307M
Cap. Flow %
-27.27%
Top 10 Hldgs %
100%
Holding
8
New
2
Increased
2
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
+$63.9M
2
NCNA
NuCana
NCNA
+$6.27M
3
TBPH icon
Theravance Biopharma
TBPH
+$4.17M
4
PRTA icon
Prothena Corp
PRTA
+$1.05M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$135M
2
GILD icon
Gilead Sciences
GILD
+$113M
3
BIVV
Bioverativ Inc. Common Stock
BIVV
+$105M
4
BIIB icon
Biogen
BIIB
+$28.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
1
Prothena Corp
PRTA
$450M
$424M 37.74%
11,557,614
+29,000
+0.3% +$1.05M
ALKS icon
2
Alkermes
ALKS
$8.25B
$305M 27.17%
5,270,428
-2,315,255
-31% -$135M
TBPH icon
3
Theravance Biopharma
TBPH
$877M
$264M 23.51%
10,898,879
+151,771
+1% +$4.17M
BIIB icon
4
Biogen
BIIB
$30.7B
$76.5M 6.81%
279,564
-91,000
-25% -$28.2M
EVFM
5
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$47.4M 4.22%
+497,703
New +$63.9M
NCNA
6
NuCana
NCNA
$6.12M
$6.24M 0.56%
+66
New +$6.27M
GILD icon
7
Gilead Sciences
GILD
$165B
– –
-1,579,353
Closed -$113M
BIVV
8
DELISTED
Bioverativ Inc. Common Stock
BIVV
– –
-1,948,325
Closed -$105M

Similar funds

LCM
Lucha Capital Management San Francisco, California $327M AUM 2.87% 1-Year Est. Return
GWA
Guidant Wealth Advisors Palatine, Illinois $269M AUM 2.79% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
IPC
Invesco Private Capital New York $365M AUM 8.08% 1-Year Est. Return
AEPG
American Economic Planning Group Warren, New Jersey $367M AUM 2.51% 1-Year Est. Return
AR
Argyll Research Wilmington, Delaware $377M AUM 4.86% 1-Year Est. Return
KCM
Keywise Capital Management Grand Cayman, Cayman Islands $220M AUM 21.27% 1-Year Est. Return
COI
Capital One Investing Mclean, Virginia $430M AUM 3.49% 1-Year Est. Return

Woodford Investment Management's Q1 2018 Portfolio in Review

As of Q1 2018, Woodford Investment Management held 8 positions worth $1.12B, down 24% from $1.48B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Woodford Investment Management withdrew a net $307M in Q1 2018, closing 2 positions and reducing 2 holdings. Its most notable exit was Gilead Sciences, an estimated $113M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Woodford Investment Management opened a new position in Evofem Biosciences, Inc. Common Stock worth $47.4M.

  • Woodford Investment Management's largest Q1 2018 buy was Evofem Biosciences, Inc. Common Stock: 497,703 shares worth $47.4M.
  • Woodford Investment Management added most to Theravance Biopharma in Q1 2018, an estimated $4.17M increase.
  • Woodford Investment Management's biggest Q1 2018 reduction was Alkermes, cutting an estimated $135M.
  • Woodford Investment Management fully exited Gilead Sciences in Q1 2018, selling an estimated $113M.
  • Woodford Investment Management's ten largest holdings make up 100% of its $1.12B portfolio in Q1 2018.
  • Woodford Investment Management opened 2 new positions and closed 2 in Q1 2018.
  • Woodford Investment Management's portfolio value fell 24% quarter-over-quarter to $1.12B.

Based on Woodford Investment Management's 13F filing for Q1 2018, filed 11 May 2018.